Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Biotechnology
- Disease
- Diagnostic
- Diagnostic Substances
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7179
License Grant
Licensor, two Italian individuals, grants to Italian Licensee an exclusive license (even as to Licensor), including the right to grant sublicenses under the Licensed Patent Rights and Licensed Technology.
License Property
Licensed Patent Rights
USSN 61/540618, filed September 29, 2011, entitled Mutations and chronic lymphoblastic leukemia.
USSN 61/540618, filed September 29, 2011, entitled Mutations and chronic lymphoblastic leukemia.
The findings have been published in the Dec 22 issue of Blood, the journal of the American Society of Hematology, in an article titled Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia association with progression and fludarabine-refractoriness (Rossi D. et al., Blood 1186904-6908, 2011). A US patent application is pending.
Field of Use
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ —
a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL).
a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL).
IPSCIO Record ID: 4269
License Grant
University hereby grants to Licensee an exclusive, worldwide License under Licensor’s rights including the right to grant subLicenses, to the Licensed Patent Rights to develop, and commercialize Licensed Products in the territory, in all fields of use.
License Property
Licensed Patent Rights
USSN 61/484330, filed May 10, 2011, entitled Hairy Cell Leukemia Biomarkers and Methods of Using Same.
USSN 61/484330, filed May 10, 2011, entitled Hairy Cell Leukemia Biomarkers and Methods of Using Same.
Field of Use
Hairy cell leukemia (HCL) is a hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a sub-type of chronic lymphoid leukemia. HCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis. The disease was formally named leukemic reticuloendotheliosis and its common name is derived from the 'hairy' appearance of the malignant B cells under a microscope.
The present invention provides, in part, a method of diagnosing hairy cell leukemia in a subject in need thereof including obtaining a biological sample from the subject and assessing the presence or absence of a BRAF mutation in the sample, wherein the presence of the BRAF mutation indicates that the subject is suffering from hairy cell leukemia. [0006] The method can further include comparing the presence, absence, or amount of the BRAF mutation in the biological sample with the presence, absence, or amount of the BRAF mutation determined in a biological sample from a subject not suffering from hairy cell leukemia or symptoms thereof. The method can be used to distinguish hairy cell leukemia cells from other forms of malignant lymphoma.
The present invention provides, in part, a method of diagnosing hairy cell leukemia in a subject in need thereof including obtaining a biological sample from the subject and assessing the presence or absence of a BRAF mutation in the sample, wherein the presence of the BRAF mutation indicates that the subject is suffering from hairy cell leukemia. [0006] The method can further include comparing the presence, absence, or amount of the BRAF mutation in the biological sample with the presence, absence, or amount of the BRAF mutation determined in a biological sample from a subject not suffering from hairy cell leukemia or symptoms thereof. The method can be used to distinguish hairy cell leukemia cells from other forms of malignant lymphoma.
IPSCIO Record ID: 46309
License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKAâ„¢ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLLâ€) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHLâ€) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
IPSCIO Record ID: 190857
License Grant
Licensor announced that the Centers for Medicare and Medicaid Services established a unique, product-specific billing code, J-code (J9034), for Bendeka. The J-code became effective on January 1, 2017. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, a chemotherapy drug used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
License Property
The original license agreement is for BENDEKAâ„¢, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLLâ€) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHLâ€) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
